Olaf Hardt R&D Reagents Miltenyi Biotec GmbH Biography Publications Institution JoVE Articles Olaf Hardt has not added a biography. If you are Olaf Hardt and would like to personalize this page please email our Author Liaison for assistance. Publications The Sialyl-glycolipid Stage-specific Embryonic Antigen 4 Marks a Subpopulation of Chemotherapy-resistant Breast Cancer Cells with Mesenchymal Features Breast Cancer Research : BCR. 2015 | Pubmed ID: 26607327 Transcriptional Pathways in CPGI2-Induced Adipocyte Progenitor Activation for Browning Frontiers in Endocrinology. 2015 | Pubmed ID: 26347713 Comparison Between Cold Plasma, Electrochemotherapy and Combined Therapy in a Melanoma Mouse Model Experimental Dermatology. Sep, 2013 | Pubmed ID: 23947672 Highly Sensitive Profiling of CD44+/CD24- Breast Cancer Stem Cells by Combining Global MRNA Amplification and Next Generation Sequencing: Evidence for a Hyperactive PI3K Pathway Cancer Letters. Dec, 2012 | Pubmed ID: 22771536 NeuroD1 Induces Terminal Neuronal Differentiation in Olfactory Neurogenesis Proceedings of the National Academy of Sciences of the United States of America. Jan, 2010 | Pubmed ID: 20080708 Gene Expression Analysis Defines Differences Between Region-specific GABAergic Neurons Molecular and Cellular Neurosciences. Nov, 2008 | Pubmed ID: 18725299 Characterization of Peptides Released from Mitochondria: Evidence for Constant Proteolysis and Peptide Efflux The Journal of Biological Chemistry. Jan, 2005 | Pubmed ID: 15556950 Utarmning av musceller från humana tumörxenotransplantat avsevärt förbättrar Nedströms analys av målceller David J. Agorku1, Stefan Tomiuk1, Kerstin Klingner2, Stefan Wild1, Silvia Rüberg1, Lisa Zatrieb1, Andreas Bosio1, Julia Schueler2, Olaf Hardt1 1R&D Reagents, Miltenyi Biotec GmbH, 2In vivo Tumorbiology, Oncotest GmbH JoVE 54259 Médecine
Utarmning av musceller från humana tumörxenotransplantat avsevärt förbättrar Nedströms analys av målceller David J. Agorku1, Stefan Tomiuk1, Kerstin Klingner2, Stefan Wild1, Silvia Rüberg1, Lisa Zatrieb1, Andreas Bosio1, Julia Schueler2, Olaf Hardt1 1R&D Reagents, Miltenyi Biotec GmbH, 2In vivo Tumorbiology, Oncotest GmbH JoVE 54259 Médecine